Abstract
The aim of this study is to determine whether the use of cardiac glycosides (CGs), drugs used in the treatment of congestive heart failure (CHF) and supra-ventricular arrhythmia, is associated with an increased risk of breast cancer. A cohort of 53,454 women newly diagnosed with CHF or supra-ventricular arrhythmia between January 1, 1988 and December 31, 2010, followed until December 31, 2012, was identified using the United Kingdom Clinical Practice Research Datalink. A nested case–control analysis was performed, where all incident cases of breast cancer occurring during follow-up were identified and matched with up to 10 controls on age, cohort entry date, and duration of follow-up. Conditional logistic regression models were used to estimate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs) of incident breast cancer associated with the use of CGs, along with measures of cumulative duration of use and dose. All analyses considered a one year lag period prior to the event, necessary for latency considerations and to minimize detection bias. The 898 breast cancer cases diagnosed beyond one year of follow-up were matched to 8,940 controls. Overall, use of CGs was not associated with an increased risk of breast cancer when compared to non-use (OR 1.07, 95 % CI 0.90–1.26). Furthermore, the risk did not vary with cumulative duration of use or cumulative dose. The findings of this large population-based study indicate that the use of CGs is not associated with an increased risk of breast cancer. This should provide reassurance to physicians and patients using these drugs.
Similar content being viewed by others
References
Biggar RJ (2012) Molecular pathways: digoxin use and estrogen-sensitive cancers–risks and possible therapeutic implications. Clin Cancer Res 18:2133–2137
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847
Camm AJ, Lip GY, De CR, Savelieva I, Atar D et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747
Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B et al (1979) Cardiac glycosides and breast cancer. Lancet 1:563
Friedman GD (1984) Digitalis and breast cancer. Lancet 2:875
Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 1:11
Ahern TP, Lash TL, Sorensen HT, Pedersen L (2008) Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 10:R102
Biggar RJ, Wohlfahrt J, Oudin A, Hjuler T, Melbye M (2011) Digoxin use and the risk of breast cancer in women. J Clin Oncol 29:2165–2170
Hartz AJ, He T (2013) Cohort study of risk factors for breast cancer in post menopausal women. Epidemiol Health 35:e2013003
Ahern TP, Tamimi RM, Rosner BA, Hankinson SE (2014) Digoxin use and risk of invasive breast cancer: evidence from the Nurses’ Health Study and meta-analysis. Breast Cancer Res Treat 144:427–435
Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425
Walley T, Mantgani A (1997) The UK general practice research database. Lancet 350:1097–1099
Delaney JA, Daskalopoulou SS, Brophy JM, Steele RJ, Opatrny L et al (2007) Lifestyle variables and the risk of myocardial infarction in the general practice research database. BMC Cardiovasc Disord 7:38
Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A et al (2003) Validity of the general practice research database. Pharmacotherapy 23:686–689
Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:e128–e136
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14
Dregan A, Moller H, Murray-Thomas T, Gulliford MC (2012) Validity of cancer diagnosis in a primary care database compared with linked cancer registrations in England. Population-based cohort study. Cancer Epidemiol 36:425–429
Boggon R, van Staa TP, Chapman M, Gallagher AM, Hammad TA et al (2013) Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf 22:168–175
Breslow NE (1996) Statistics in epidemiology: the case-control study. J Am Stat Assoc 91:14–28
Biggar RJ, Andersen EW, Kroman N, Wohlfahrt J, Melbye M (2013) Breast cancer in women using digoxin: tumor characteristics and relapse risk. Breast Cancer Res 15:R13
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE et al (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–1593
Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X et al (2009) Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res 69:2739–2747
Holmes MD, Chen WY (2012) Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 14:216
Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I et al (2012) Anticancer activity of cardiac glycosides: at the frontier between cell-autonomous and immunological effects. Oncoimmunology 1:1640–1642
Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ (2012) Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 1:4
Kometiani P, Liu L, Askari A (2005) Digitalis-induced signaling by Na +/K + -ATPase in human breast cancer cells. Mol Pharmacol 67:929–936
Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J et al (2009) Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One 4:e8292
Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y et al (2012) Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 4:143ra99
Falconer IR, Beresford AM, Jones A, Vacek AT (1983) Effect of digoxin on DNA synthesis and cell viability in human breast tumour tissue in organ culture. Chemotherapy 29:368–372
Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA et al (2005) Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 68:1642–1645
Zhang H, Qian DZ, Tan YS, Lee K, Gao P et al (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 105:19579–19586
Wong CC, Zhang H, Gilkes DM, Chen J, Wei H et al (2012) Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 90:803–815
Rifka SM, Pita JC Jr, Loriaux DL (1976) Mechanism of interaction of digitalis with estradiol binding sites in rat uteri. Endocrinology 99:1091–1096
Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL (1978) Interaction of digitalis and spironolactone with human sex steroid receptors. J Clin Endocrinol Metab 46:338–344
Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH (2004) Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 79:282–288
Smith NL, Chan JD, Rea TD, Wiggins KL, Gottdiener JS et al (2004) Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J 148:710–717
Pilote L, Eisenberg MJ, Essebag V, Tu JV, Humphries KH et al (2013) Temporal trends in medication use and outcomes in atrial fibrillation. Can J Cardiol 29:1241–1248
Acknowledgments
This study was funded in part by the Canadian Institutes of Health Research.
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Couraud, S., Dell’Aniello, S., Bouganim, N. et al. Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia. Breast Cancer Res Treat 146, 619–626 (2014). https://doi.org/10.1007/s10549-014-3058-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3058-8